Number of the records: 1
Third-generation taxanes SB-T-121605 and SB-T-121606 are effective in pancreatic ductal adenocarcinoma
- 1.
SYSNO ASEP 0584812 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Third-generation taxanes SB-T-121605 and SB-T-121606 are effective in pancreatic ductal adenocarcinoma Author(s) Sychra, T. (CZ)
Spalenkova, A. (CZ)
Balatka, S. (CZ)
Václavíková, R. (CZ)
Šeborová, K. (CZ)
Ehrlichová, M. (CZ)
Truksa, Jaroslav (BTO-N) RID, ORCID
Sandoval-Acuna, Cristian (BTO-N)
Němcová, V. (CZ)
Szabo, A. (CZ)
Kočí, K. (CZ)
Tesarova, T. (CZ)
Chen, L. (US)
Ojima, I. (US)
Oliverius, M. (CZ)
Souček, P. (CZ)Number of authors 16 Article number 109044 Source Title iScience. - : Cell Press
Roč. 27, č. 2 (2024)Number of pages 15 s. Language eng - English Country US - United States Keywords biological evaluation ; cancer ; microenvironment ; cytotoxicity ; transport ; design Subject RIV EB - Genetics ; Molecular Biology OECD category Biochemistry and molecular biology R&D Projects GA21-14082S GA ČR - Czech Science Foundation (CSF) Method of publishing Limited access Institutional support BTO-N - RVO:86652036 UT WOS 001182148700001 EID SCOPUS 85184767975 DOI 10.1016/j.isci.2024.109044 Annotation Pancreatic cancer is a severe malignancy with increasing incidence and high mortality due to late diagnosis and low sensitivity to treatments. Search for the most appropriate drugs and therapeutic regimens is the most promising way to improve the treatment outcomes of the patients. This study aimed to compare (1) in vitro efficacy and (2) in vivo antitumor effects of conventional paclitaxel and the newly synthesized second (SB-T-1216) and third (SB-T-121605 and SB-T-121606) generation taxanes in KRAS wild type BxPC-3 and more aggressive KRAS G12V mutated Paca-44 pancreatic cancer cell line models. In vitro, paclitaxel efficacy was 27.6 G 1.7 nM, while SB-Ts showed 1.7-7.4 times higher efficacy. Incorporation of SB-T121605 and SB-T-121606 into in vivo therapeutic regimens containing paclitaxel was effective in suppressing tumor growth in Paca-44 tumorbearing mice at small doses (%3 mg/kg). SB-T-121605 and SB-T121606 in combination with paclitaxel are promising candidates for the next phase of preclinical testing. Workplace Institute of Biotechnology Contact Monika Kopřivová, Monika.Koprivova@ibt.cas.cz, Tel.: 325 873 700 Year of Publishing 2025 Electronic address https://www.sciencedirect.com/science/article/pii/S2589004224002657?via%3Dihub
Number of the records: 1